An expert in environmental toxins at The University of Nottingham has developed a new antifungal technology which has the potential to play a major role in securing future food supplies.
Blocking fungal growth
Professor Simon Avery from the University’s Faculty of Medicine and Health Sciences has discovered that two agents, when combined, affect the process of protein synthesis, and have the potential to effectively block fungal growth in certain types of fungi which cause disease in crops or in humans.
Crop losses due to fungal spoilage each year are equivalent to the amount of food that could feed up to four billion people. In the developed world, millions of tonnes of crops are ruined each year by fungi and the problem is especially acute in developing countries where access to fungicides is more limited.
One of the problems with fungicides is that in many cases, the fungi adapt to the treatment, which means that most fungicides are only effective for a limited period. The solution developed by the University uses two agents which should make it more difficult for the fungi to acquire resistance to the fungicide.
Explaining how the technology works, Professor Avery said: “Protein synthesis is essential to enable organisms to grow. When these two agents are applied it causes errors in the synthesis process that stop the fungus growing.”
After making the breakthrough discovery, which is patented by the University, Professor Avery and his team received initial development support through the University’s HERMES scheme. This enabled him to secure additional funding from the Biotechnology and Biological Science and Research Council (BBSRC) to further develop the technology. Field trials will take place this summer to study the impact of the fungicides on crops which are subjected to different environmental conditions.
The Latest on: Antifungal technology
via Google News
The Latest on: Antifungal technology
- Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2020 Results - Earnings Call Transcripton August 11, 2020 at 12:14 am
Q2 2020 Earnings Conference Call August 10, 2020, 04:30 PM ET Company Participants Peter Vozzo - IR Jerry Jabbour - CEO Terri Matkovits - Chief Development Officer Conference Call Participants Michael ...
- Anti-microbial/Anti-fungal Tests Market Research, Key Players, Trade Segments And Forecast To 2020-2026on August 10, 2020 at 9:23 am
The MarketWatch News Department was not involved in the creation of this content. Aug 10, 2020 (Heraldkeepers) -- The Anti-microbial/Anti-fungal Tests Market is ...
- Coronavirus in Pune: DIAT develops low-cost bed isolation system for COVID-19 patientson July 31, 2020 at 1:59 am
The Defence Institute of Advanced Technology (DIAT ... The envelope is reusable as it is antibacterial-antifungal and can be sanitized," a PIB press release read. "Each envelope is capable ...
- Innovation Pharmaceuticals Grants Licensing Rights to Fox Chase Chemical Diversity Center, Inc. for Antifungal Technologyon July 22, 2020 at 5:00 am
Over $5 million in government grants have helped fund antifungal work conducted to date. Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world ...
- Innovation Pharmaceuticals Grants Licensing Rights to Fox Chase Chemical Diversity Center, Inc. for Antifungal Technologyon July 22, 2020 at 1:00 am
WAKEFIELD, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company and ...
- Innovation Pharmaceuticals Grants Licensing Rights to Fox Chase Chemical Diversity Center, Inc. for Antifungal Technologyon July 21, 2020 at 10:00 pm
Over $5 million in government grants have helped fund antifungal work conducted to date. Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class ...
via Bing News